Brief: Traws Pharma Provides Updated Guidance On Influenza Prophylaxis Program
22/06/2026 12:46
BRIEF-Traws Pharma Provides Updated Guidance On Influenza Prophylaxis Program June 22 (Reuters) - Traws Pharma Inc TRAW.O:
TRAWS PHARMA PROVIDES UPDATED GUIDANCE ON INFLUENZA PROPHYLAXIS PROGRAM
TRAWS PHARMA - PREPARING UPDATED TOXICOLOGY DATA FOR MHRA TIVOXAVIR MARBOXIL PHASE 2A STUDY
TRAWS PHARMA - UPDATED DATA PACKAGE TO BE RESUBMITTED TO MHRA IN Q3 2026
TRAWS PHARMA - COMPANY EXPECTS MHRA RESPONSE WITHIN 30 DAYS OF RESUBMISSION
TRAWS PHARMA - COMPANY TO INITIATE PROFILING OF ADDITIONAL MOLECULES FOR INFLUENZA TREATMENT PROGRAM
Source text: ID:nGNXbMtG2x
Further company coverage: TRAW.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Traws Pharma
See all newsBrief: Traws Pharma - Enters Stock Purchase Agreement With Roth Principal Investments On Oct 23, 2026 - SEC Filing
Traws Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Traws Pharma Q2 revenue falls to zero on licensing termination; net loss widens
Traws Pharma Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Traws Pharma Provides Updated Guidance On Influenza Prophylaxis Program